Ashraf Mansour, MD
Internal Medicine · Elizabeth, NJNPI 1952402398
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $14,366 of the $17,346 with a category attached, or 82.8%. It is spread thinly across 40 manufacturers, the largest accounting for just 19.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $5,408 and has fallen 78.3% since, to $1,174 in 2025. Among internal medicine clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 722 payments — averaging $24.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- Silk Road Medical, Inc.$3K
- Philips North America LLC$2K
- W. L. Gore & Associates, Inc.$1K
- Boehringer Ingelheim$1K
- E.r. Squibb & Sons, L.L.C.$913
- plus $6K from 34 others
What the payments were for
- Travel & lodging$2,95817%
- Food & beverage$14,36683%
- Education$220%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ENROUTE Transcarotid Stent$3,063
- ENROUTE Transcarotid Neuroprotection System$3,063
- BREZTRI$1,094
- ELIQUIS$509
- FARXIGA$469
- EXCLUDER AAA Endoprosthesis$344
- CAMZYOS$250
- JARDIANCE$249
- AIRSUPRA$230
- GORE ACUSEAL Cardiovascular Patch Vascular$212
- JETi All In One Non-Sterile Kit$199
- GORE EXCLUDER AAA Endoprosthesis$197
- EXCLUDER Conformable AAA Endoprosthesis with Active Control$186
- GORE VIABAHN VBX Balloon Expandable Endo$181
- Indigo System$160
- C3 Delivery System$138
- TRELEGY ELLIPTA$124
- AIMOVIG$103
- INVOKANA$102
How this compares
$17,346 in reported general payments places this provider in the 95th percentile of 4,032 internal medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 216 | $139,713 |
| LinzessLinaclotide | 66 | $75,749 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 17 | $66,346 |
| OzempicSemaglutide | 42 | $55,599 |
| JardianceEmpagliflozin | 66 | $52,589 |
| FarxigaDapagliflozin Propanediol | 54 | $52,020 |
| EliquisApixaban | 68 | $46,713 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 63 | $35,289 |
| VascepaIcosapent Ethyl | 39 | $32,637 |
| JanuviaSitagliptin Phosphate | 16 | $22,131 |
| JanumetSitagliptin Phos/Metformin Hcl | 17 | $14,328 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 450 | $10,949 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 22 | $10,653 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $9,577 |
| MyrbetriqMirabegron | 18 | $8,969 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaBreztri Aerosphere, Farxiga, Symbicort | $3,419 | $195,593287 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $1,101 | $87,878129 claims |
| AbbVieLinzess | $355 | $75,74966 claims |
| GileadBiktarvy | $44 | $66,34617 claims |
| Novo NordiskOzempic | $453 | $55,59942 claims |
| MerckJanuvia, Janumet | $648 | $36,45933 claims |
| GSKAnoro Ellipta, Trelegy Ellipta | $444 | $20,23035 claims |
| Astellas Pharma US IncMyrbetriq | $88 | $8,96918 claims |
| Scilex Pharmaceuticals Inc.Colchicine | $57 | $3,29025 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,032 internal medicine providers in New Jersey.
Other internal medicine in Elizabeth
- Sanjay BattaElizabeth$28K
- David ShulkinMorristown$1.7M
- Howard UdermanLakewood$955K
- Darshi SunderamEast Orange$530K
- Annika DrongeEmerson$401K
- Stephen MarcellaNew Brunswick$331K
- Viju VijaysadanKinnelon$325K
- Mark MonaneWoodcliff Lake$268K
- Martin BedigianLivingston$240K
- Rameck HuntPlainsboro$217K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.